TY  - JOUR
AU  - Alors-Perez, Emilia
AU  - Blázquez-Encinas, Ricardo
AU  - Alcalá, Sonia
AU  - Viyuela-García, Cristina
AU  - Pedraza-Arevalo, Sergio
AU  - Herrero-Aguayo, Vicente
AU  - Jiménez-Vacas, Juan M
AU  - Mafficini, Andrea
AU  - Sánchez-Frías, Marina E
AU  - Cano, María T
AU  - Abollo-Jiménez, Fernando
AU  - Marín-Sanz, Juan A
AU  - Cabezas-Sainz, Pablo
AU  - Lawlor, Rita T
AU  - Luchini, Claudio
AU  - Sánchez, Laura
AU  - Sánchez-Hidalgo, Juan M
AU  - Ventura, Sebastián
AU  - Martin-Hijano, Laura
AU  - Gahete, Manuel D
AU  - Scarpa, Aldo
AU  - Arjona-Sánchez, Álvaro
AU  - Ibáñez-Costa, Alejandro
AU  - Sainz, Bruno
AU  - Luque, Raúl M
AU  - Castaño, Justo P
PY  - 2021
DO  - 10.1186/s13046-021-02153-9
UR  - https://hdl.handle.net/10668/25885
T2  - Journal of experimental & clinical cancer research : CR
AB  - Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, requiring novel treatments to target both cancer cells and cancer stem cells (CSCs). Altered splicing is emerging as both a novel cancer hallmark and an attractive therapeutic target....
LA  - en
KW  - Pancreatic cancer
KW  - Pladienolide-B
KW  - SF3B1
KW  - Splicing-spliceosome
KW  - cancer stem cells
KW  - Adenocarcinoma
KW  - Adult
KW  - Aged
KW  - Animals
KW  - Carcinoma, Pancreatic Ductal
KW  - Disease Models, Animal
KW  - Female
KW  - Humans
KW  - Male
KW  - Mice
KW  - Middle Aged
KW  - Neoplastic Stem Cells
KW  - Phosphoproteins
KW  - RNA Splicing Factors
KW  - Zebrafish
TI  - Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
TY  - research article
VL  - 40
ER  -